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Background and Objective. Previous small studies suggest that chronic atrophic gastritis is common in dermatitis herpetiformis
(DH). We here examined the frequency and topography of chronic gastritis in 93 untreated DH subjects and in 186 controls with
dyspepsia. Methods. Specimens were drawn from the gastric corpus and antrum and examined for atrophy, intestinal metaplasia,
and Helicobacter pylori. Duodenal biopsies were taken. Results. Atrophic corpus gastritis was more frequent in DH than in controls
(16.0% and 2.7%, resp., P<0.001); atrophy in the antrum was rare in both groups (3.2% and 1.1%, P = 0.34). Intestinal meta-
plasia was present in 13 (14.0%) DH and 12 (6.5%) control patients (P = 0.038) and H. pylori in 17 (18.3%) and 17 (9.3%)
(P = 0.028), respectively. Small-bowel villous atrophy was seen in 76% of the DH patients, equally in patients with and without
chronic gastritis. One DH patient with atrophic gastritis developed gastric cancer. Conclusion. In DH, chronic atrophic gastritis
was common in the corpus, but not in the antrum. H. pylori will partly explain this, but corpus atrophy is suggestive of an auto-
immune etiology. Atrophic gastritis may increase the risk of gastric cancer. We advocate performing upper endoscopy with suﬃ-
cient histologic samples in DH.
1.Introduction
The majority of patients with dermatitis herpetiformis (DH)
evincesmall-bowelmucosaldamageorinﬂammationsimilar
to that in classic or early-stage celiac disease [1, 2]. Patients
rarely suﬀer from abdominal symptoms, and irrespective of
small-bowel mucosal morphology, the rash in DH responds
toagluten-freediet,thetreatmentofchoiceforthecondition
[3, 4]. Coeliac disease and DH share a similar genetic back-
ground and occur frequently in the same families; even iden-
tical twins may have diﬀerent phenotypes [5, 6]. Tissue-type
transglutaminase is the major autoantigen in coeliac disease,
but an immune response to epidermal transglutaminase is
probably essential for the development of DH, although this
is not fully proven [7, 8]. Altogether, DH is indisputably an
extraintestinal manifestation of coeliac disease.
Again similarly to coeliac disease, autoimmune condi-
t i o n so c c u rt o g e t h e rw i t hD H[ 9]. Earlier studies indicate
that chronic atrophic gastritis (CAG) is common in DH and
may be of autoimmune origin, but the data are based on a
limited number of patients only [10–12]. Helicobacter pylori
infection is the main agent causing chronic gastritis [13, 14],
butautoimmunegastritismayalsooccur.H.pylorigastritisis
often patchy and aﬀects the antral mucosa, whereas autoim-
mune gastritis occurs typically in the corpus of the stomach.
TheSydneySystemisasystematicapproachtodetermine
the topography, morphology, etiology, and severity of gastri-
tis [15]. It has not previously been applied in DH. Small-
intestinal biopsy helps to estimate the severity of villous
atrophy but is not necessary for the ultimate diagnosis of
DH.ProvidedthatCAGiscommoninpatientswithDH,this2 Clinical and Developmental Immunology
Table 1: Gastric ﬁndings in the 93 patients with dermatitis herpetiformis (female 40, median age 48 years; range 7–76) and 186 control
patients with dyspepsia (female 80, median age 56 years; range 18–86).
Dermatitis herpetiformis
n = 93
Control patients
n = 186 Odds ratio P-value
Corpus atrophy 15(16.0%) 5(2.7%) 6.96(CI 2.29–25.16) <0.001
Antrum atrophy 3(3.2%) 2(1.1%) 3.07(CI 0.34–37.16) 0.34
Intestinal metaplasia1 13(14.0%)2 12(6.5%)3 2.36(CI 1.05–5.30) 0.038
Helicobacter pylori1 17(18.3%) 17(9.1%) 2.22(CI 1.09–4.54) 0.028
1in corpus or antrum.
2antrum 8, corpus 8.
3antrum 8, corpus 5.
would constitute a further indication for endoscopy. In the
present study we examined the occurrence of CAG and H.
pylori, as classiﬁed by the Sydney System, in a large series of
DH patients sampled over the past 20 years. The histologic
data were compared to those from patients of similar sex and
age who were suﬀering from dyspepsia.
2.MaterialandMethods
The study was carried out over the period 1990–2009 at the
Department of Dermatology, Tampere University Hospital.
The cohort comprised 93 patients with DH, from whom
biopsy samples had been taken from duodenum and from
stomach for the classiﬁcation of gastritis according to the
SydneySystem.ThediagnosisofDHwasbasedonthetypical
clinical picture and direct immunoﬂuorescence showing
granular IgA deposits in the papillary dermis in the unin-
volved skin [16]. Patients’ medical records were examined.
Duodenal biopsy specimens were graded as subtotal villous
atrophy, partial villous atrophy, and normal mucosa. Gastric
mucosal atrophy was graded from 0 to 3, grade 0 indicating
normal morphology and 3 the most severe involvement,
in line with the Sydney System [15]. H. pylori was not
graded, since a positive ﬁnding anywhere in the stomach
was considered diagnostic for the infection. The patients
with DH were regularly followed up in the special outpatient
clinic for 1-2 years [17]. A questionnaire was sent to all DH
patients who were alive in 2011, and it included questions on
adherence to the gluten-free diet, the use of dapsone, and the
occurrence of associated diseases and malignancies.
The control group comprised patients suﬀering from
dyspepsia and undergoing upper gastrointestinal endoscopy
at the Regional Hospital of our catchment area in 2009–
2011. Two control patients of similar sex and age (±5y e a r s )
and no small-bowel mucosal villous atrophy were chosen for
each DH case, the ﬁnal series thus consisting of 186 control
subjects.
The statistical diﬀerences between DH and control
patients and DH patients with and without CAG were cal-
culated by chi-square test or Fisher’s exact test when appro-
priate.Oddsratiosweregivenwith95%conﬁdenceintervals.
The study was based on the case records, and permission
to read these was obtained. A statement of the Ethical
Committee was not considered obligatory.
3. Results
Atrophy of the corpus and intestinal metaplasia were signif-
icantly more common in DH than in the control subjects
(Table 1). By contrast, there was no signiﬁcant diﬀerence
between the groups in the occurrence of antral atrophy,
which was altogether a relatively uncommon ﬁnding. The
mean score for atrophy in the corpus was 1.6 in DH patients
and 2.3 in control subjects.
Seven (44%) DH patients with CAG had associated in-
testinal metaplasia in the body of the stomach and additional
two patients in the antrum (Table 2). H. pylori infection was
signiﬁcantly more frequent in DH than in controls (18%
and 9%, resp., Table 1). One patient (no. 3, Table 2)w i t h
pangastritis and intestinal metaplasia in the initial biopsy
developed gastric cancer one year later. Forty-four percent
of DH patients with CAG showed H. pylori in the gastric
mucosa, compared to 14% without CAG (Table 3).
Table 3 shows the 16 DH patients with CAG to be older
(mean 63 years) than the 78 without (mean 44 years). Small-
intestinalvillousatrophywasfoundin76.6%ofpatientswith
DH and was equally common in patients with and without
CAG. Thirty percent of patients with DH reported abdomi-
nal complaints; again, there was no signiﬁcant diﬀerence be-
tween patients with or without CAG (Table 3).
All 16 DH patients with CAG started a gluten-free diet
after the diagnosis of DH, nine in addition using daily 25mg
to 50mg of dapsone to control the rash. All maintained a
strict diet and no longer needed dapsone at the end of the
followup.
Associated autoimmune diseases were found in three DH
patients with CAG; one had hypothyroidism, one pernicious
anaemia and Graves’ disease, and one vitiligo (Table 2). One
DH patient with CAG developed prostate cancer, and two
patients had had breast cancer before the diagnosis of DH.
4. Discussion
The frequency of CAG in the corpus was signiﬁcantly more
common in the DH patients than in the control subjects
suﬀering from dyspepsia. No such a diﬀerence was seen in
the antrum of the stomach. Previously, Primignani et al. [12]
conducted a study in 57 Italian patients with DH and found
a prevalence of CAG of 30%, compared to 15% in non-DHClinical and Developmental Immunology 3
T
a
b
l
e
2
:
G
a
s
t
r
i
c
a
n
d
d
u
o
d
e
n
a
l
ﬁ
n
d
i
n
g
s
,
d
a
p
s
o
n
e
,
a
n
d
g
l
u
t
e
n
-
f
r
e
e
d
i
e
t
(
G
F
D
)
t
r
e
a
t
m
e
n
t
,
a
n
d
a
s
s
o
c
i
a
t
e
d
d
i
s
e
a
s
e
s
a
n
d
m
a
l
i
g
n
a
n
c
i
e
s
i
n
1
6
d
e
r
m
a
t
i
t
i
s
h
e
r
p
e
t
i
f
o
r
m
i
s
(
D
H
)
p
a
t
i
e
n
t
s
w
i
t
h
c
h
r
o
n
i
c
a
t
r
o
p
h
i
c
g
a
s
t
r
i
t
i
s
.
P
a
t
i
e
n
t
n
o
.
S
e
x
/
a
g
e
(
y
e
a
r
s
)
Y
e
a
r
o
f
D
H
d
i
a
g
n
o
s
i
s
G
a
s
t
r
i
c
ﬁ
n
d
i
n
g
s
D
u
o
d
e
n
a
l
h
i
s
t
o
l
o
g
y
a
t
d
i
a
g
n
o
s
i
s
/
o
n
G
F
D
A
s
s
o
c
i
a
t
e
d
a
u
t
o
i
m
m
u
n
e
d
i
s
e
a
s
e
s
a
n
d
m
a
l
i
g
n
a
n
c
i
e
s
C
o
r
p
u
s
a
t
r
o
p
h
y
/
m
e
t
a
p
l
a
s
i
a
1
A
n
t
r
u
m
a
t
r
o
p
h
y
/
m
e
t
a
p
l
a
s
i
a
1
H
e
l
i
c
o
b
a
c
t
e
r
p
y
l
o
r
i
1
F
/
5
3
1
9
9
6
1
/
1
0
/
0
−
P
V
A
B
r
e
a
s
t
c
a
n
c
e
r
1
9
9
2
2
F
/
6
9
1
9
9
9
1
/
0
0
/
0
−
P
V
A
—
3
M
/
6
8
2
0
0
0
1
/
2
2
/
2
−
P
V
A
/
N
G
a
s
t
r
i
c
c
a
n
c
e
r
2
0
0
1
4
M
/
6
4
2
0
0
1
3
/
2
0
/
0
−
P
V
A
/
N
H
y
p
o
t
h
y
r
e
o
s
i
s
>
1
0
y
r
s
b
e
f
o
r
e
D
H
d
i
a
g
n
o
s
i
s
P
r
o
s
t
a
t
e
c
a
n
c
e
r
2
0
1
0
5
M
/
6
1
2
0
0
1
1
/
0
0
/
1
−
N
/
N
—
6
F
/
5
8
2
0
0
1
1
/
0
0
/
0
+
P
V
A
/
N
—
7
F
/
6
2
2
0
0
1
2
/
0
0
/
0
−
P
V
A
B
r
e
a
s
t
c
a
n
c
e
r
1
9
9
2
8
M
/
5
7
2
0
0
1
1
/
0
0
/
0
+
P
V
A
—
9
M
/
4
8
2
0
0
2
1
/
0
0
/
0
+
N
—
1
0
M
/
7
1
2
0
0
3
2
/
1
0
/
0
−
N
V
i
t
i
l
i
g
o
2
0
0
3
1
1
F
/
5
6
2
0
0
3
3
/
1
0
/
0
−
P
V
A
/
N
P
e
r
n
i
c
i
o
u
s
a
n
e
m
i
a
2
0
0
4
G
r
a
v
e
s
’
d
i
s
e
a
s
e
2
0
0
5
1
2
M
/
7
1
2
0
0
4
2
/
1
0
/
2
+
N
—
1
3
M
/
7
6
2
0
0
6
3
/
2
0
/
1
−
N
—
1
4
F
/
7
4
2
0
0
7
1
/
0
1
/
0
+
P
V
A
—
1
5
F
/
6
3
2
0
0
7
1
/
0
0
/
0
+
S
V
A
—
1
6
M
/
6
9
2
0
0
8
0
/
0
2
/
2
+
S
V
A
—
S
V
A
:
s
u
b
t
o
t
a
l
v
i
l
l
o
u
s
a
t
r
o
p
h
y
,
P
V
A
:
p
a
r
t
i
a
l
v
i
l
l
o
u
s
a
t
r
o
p
h
y
,
N
:
n
o
r
m
a
l
m
u
c
o
s
a
a
t
d
i
a
g
n
o
s
i
s
a
n
d
o
n
a
g
l
u
t
e
n
-
f
r
e
e
d
i
e
t
(
G
F
D
)
.
1
s
c
o
r
e
0
–
3
a
c
c
o
r
d
i
n
g
t
o
t
h
e
S
y
d
n
e
y
S
y
s
t
e
m
.4 Clinical and Developmental Immunology
Table 3: Data on 94 patients with dermatitis herpetiformis. Comparison between cases with and without chronic atrophic gastritis (CAG).
DH patients with CAG
n = 16
DH patients without CAG
n = 78 P-value
Mean age at diagnosis years (range) 63.0 (47–76) 43.9 (7–76)
Men 9 (56.3%) 45 (57.7%)
Duodenal histology
(i) partial or subtotal villous atrophy 11 (68.8%) 61 (78.2%)
17 (21.8%) 0.52
(ii) normal mucosa 5 (31.2%)1
Helicobacter pylori 7 (44.0%) 11 (14.1%) 0.012
Abdominal complaints 5 (31.2%) 23 (40.4%)1 0.36
DH: dermatitis herpetiformis.
1Data available on 57 patients.
control subjects with dyspepsia (P<0.05). Patients with DH
do not usually suﬀer from dyspepsia, and therefore the con-
trol group was not analogous to the study group. Storskrubb
et al. [18] carried out esophago-gastroduodenoscopy at ran-
dom for 1000 Swedish adults. The overall frequency of cor-
pus atrophy was 5% and antrum atrophy 2%. Our data thus
indicatethatatrophiccorpusgastritisismorecommoninpa-
tients with DH than in the population in general.
H.pyloriinfectioniscommoninCAG[13,14,19].Inline
with this, the present DH patients with CAG had H. pylori
signiﬁcantly more often than those without CAG. This may
be partly explained by the age diﬀerence; H. pylori is more
common in older people, and our patients with GAG were
older that those without (Table 3). However, the presence of
H. pylori in all DH patients (18.3%) was signiﬁcantly higher
than among dyspeptic control subjects with a similar age
distribution (9.1%, Table 1). By comparison, Crabtree et al.
[20] examined 58 DH patients in Britain and by serological
methods found H. pylori IgG antibodies in 63% of patients,
this frequency being however only slightly higher than in
other dermatological patients.
There are some limitations to the present study. It was
based on the case records, and it was not possible to re-read
the biopsy samples. Nevertheless, we considered that the
activity of gastritis, as deﬁned by the Sydney System, [15]
would have been unreliable to analyze here. Circulating
parietal cell and intrinsic factor antibodies could not be
determined.OurDHpatientswererecruitedduringtheyears
1990–2009,whereasthecontrolswereenrolledlater,in2009–
2011.Thismayhaveaﬀectedtheresultsinthatduringthelast
decades, the prevalence of H. pylori has decreased in Finland
and elsewhere [21]. However, all but two DH patients
with CAG and also patients with H. pylori were diagnos-
ed in 2000–2009.
Previous studies have shown that patients with DH simi-
lar to those with celiac disease frequently have associated au-
toimmune conditions such as thyroid diseases and insulin-
dependent diabetes mellitus [9, 22, 23]. In the present study
two DH patients with CAG had thyroid disease, one of them
also pernicious anemia and one patient vitiligo. Due to the
limitations of the study, we cannot be sure whether the
CAG in the present DH patients was of autoimmune origin.
However, this is quite possible judging from the topography
of CAG, that is antrum-sparing gastritis [15], and the overall
autoimmune nature of DH [23].
CAG is known to be associated with an increased risk
of gastric cancers, which seems to decrease after eradication
of H. pylori [24, 25]. One of our DH patients with CAG
developed gastric cancer one year after the diagnosis of DH.
Prior to this, he had shown pangastric atrophy and moderate
intestinal metaplasia without H. pylori infection. The patient
had adhered strictly to a gluten-free diet since the diagnosis;
the small-bowel mucosa showed no atrophy, and the rash
was controlled without dapsone. Similarly, the small-bowel
mucosa and the rash in the other DH patients with CAG
respondedwelltoGFDtreatment.Incontrast,CAGpersisted
in all 4 patients subjected to control biopsies, indicating that
CAG in DH does not respond to gluten withdrawal, as also
previously documented [26, 27]. Patients with DH run an
increased risk of lymphoma [28, 29], but previous large DH
studies have not shown any increased risk of gastric or other
cancers [28, 30]. Whether persisting CAG in DH involv-
es a risk of gastric cancer is a possibility which should be ex-
amined in further studies.
5. Conclusion
The present controlled study showed that patients with DH
have at the time of the diagnosis a signiﬁcantly increased fre-
quency of CAG in the corpus but not in the antrum. In addi-
tion to H. pylori infection, autoimmune mechanisms may be
implicated in the development of gastritis. The DH patients
here did not present with any speciﬁc gastrointestinal symp-
toms.OneDHpatientwithCAGdevelopedgastriccancer.In
untreated DH we recommend upper gastrointestinal endo-
scopy, upon which biopsy specimens should be taken not
only from the duodenum but also from the gastric corpus
and antrum.
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